Clinical Trial Update: A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating risankizumab for moderately to severely active Crohn's disease has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2022-07-06